Immediate-Release Tablets: Design, Pharmacokinetics, and Clinical Use

Definition

Immediate-release (IR) tablets disintegrate and release the active pharmaceutical ingredient (API) rapidly after oral administration, without deliberate rate-modifying mechanisms.

Key Characteristics

• Disintegration time: Typically <15 min (USP <701>).
• Absorption: Rate-limited by gastric emptying, solubility, permeability.
• T_max: Usually 30–120 min post-dose.
• Peak-trough fluctuations: Higher C_max, shorter half-life vs. modified-release.

Excipients

• Diluents (lactose, microcrystalline cellulose)
• Binders (povidone, HPMC)
• Disintegrants (croscarmellose sodium, sodium starch glycolate) — critical for rapid breakup
• Lubricants (magnesium stearate)

Comparison with Modified-Release Forms

Feature	Immediate-Release	Extended/Controlled-Release
Dosing frequency	Multiple daily (q4–8h)	Once or twice daily
Cmax/Cmin ratio	High	Low
Adherence	Lower	Higher
Flexibility	Dose titration easy	Fixed ratios; cannot crush

Clinical Considerations

• Food effects: some IR formulations require empty stomach (e.g., bisphosphonates, levothyroxine).
• Crushing generally acceptable unless enteric-coated or sublingual.
• Preferred for acute conditions, titration phases, drugs with wide therapeutic index.